CheckMate 9LA: 4‑y Clinical update
The CheckMate 9LA study has already demonstrated the significant benefit of combining nivolumab and ipilimumab with two cycles of chemotherapy in terms of overall survival compared to chemotherapy alone. Due to its favourable risk-benefit profile, this treatment approach has emerged as a viable first-line option for patients with advanced non-small-cell lung cancer (NSCLC). During ASCO 2023, updated findings on the efficacy and safety of this combination with a minimum follow-up of 4 years were reported. Additionally, exploratory analyses were conducted to assess the efficacy of this treatment based on the histologic subtype of the tumour, which is a known prognostic indicator for NSCLC.
Prof. Dr Christophe Dooms from the University Hospital Gasthuisberg in Leuven meticulously examines and discusses these data, comprehensively analysing the findings.
With the educational support of:
